Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node Positive and High Risk Node Negative Patients With Operable Breast Cancer Containing The HER2 Alteration
Brief Summary: Primary objective:

* Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin.

Secondary objective:

* Compare overall survival of participants treated with these regimens.
* Compare the toxic effects (including cardiac) of these regimens in these participants.
* Compare quality of life of participants treated with these regimens.
* Compare pathologic and molecular markers for predicting efficacy of these regimens in these participants.
* For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with fluorescence in situ hybridization in predicting outcome in participants treated with these regimens.


Options:
A: Arm Label: Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate | Arm Label: Arm II (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Arm Label: Arm III (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Intervention Type: DRUG; Name: Aromatase Inhibition Therapy; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Tamoxifen Citrate; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: BIOLOGICAL; Name: Trastuzumab; Assigned to Arm(s): Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen)
B: Arm Label: Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Docetaxel | Arm Label: AC followed by Docetaxel + Herceptin (AC→TH); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Docetaxel, Drug: Herceptin | Arm Label: Docetaxel + Carboplatin + Herceptin (TCH); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Herceptin, Drug: Carboplatin | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Docetaxel + Carboplatin + Herceptin (TCH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Docetaxel + Carboplatin + Herceptin (TCH) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Docetaxel + Carboplatin + Herceptin (TCH)
C: Arm Label: Observation Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Herceptin 1-Year Arm; Type: EXPERIMENTAL; Interventions: Drug: Herceptin | Arm Label: Herceptin 2-Year Arm; Type: EXPERIMENTAL; Interventions: Drug: Herceptin | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): Herceptin 1-Year Arm | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): Herceptin 2-Year Arm
D: Arm Label: Arm 1: adriamycin + cyclophosphamide then taxol; Type: ACTIVE_COMPARATOR; Interventions: Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Arm Label: Arm 2: adriamycin + cyclophosphamide then taxol + herceptin; Type: EXPERIMENTAL; Interventions: Biological: herceptin, Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Intervention Type: BIOLOGICAL; Name: herceptin; Assigned to Arm(s): Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: adriamycin; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: taxol; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin

Answer: B